Based on a subgroup of the KEYNOTE-001 trial, in which a small number of EGFRm, TKI-naïve patients experienced improved objective response rate (ORR) compared to TKI-pretreated patients, the follow up Phase II NCT02879994 trial evaluated pembrolizumab first-line therapy in TKI-naïve, EGFRm advanced NSCLC patients with PD-L1 positivity (TPS ≥ 1%) (38, 58). Here, CD274 is linked to non-small cell lung carcinoma.